DarioHealth Appoints Claudia Rimerman Kraut as Vice President of Broker and Consultant Partnerships
Prior senior management roles at Omada Health, American Well, AIG, United Healthcare, and Humana
NEW YORK, January 7, 2021 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, announced today the appointment of Claudia Rimerman Kraut as Vice President of Broker and Consultant Partnerships. In the newly created role, Ms. Kraut will be a senior member of the employer sales team and lead Dario's benefit consultant and alliance outreach as part of the self-insured employers and managed care sales organization. Ms. Kraut brings a strong combination of benefits, partnerships, and digital health experience, most recently as Director of Alliances at Omada Health, where she successfully grew alliances with benefits consultants and other partners. She has also held senior positions at American Well, United Health, AIG, Humana and MetLife.
"We believe that Claudia's deep expertise and relationships in healthcare and digital therapeutics will strengthen our commercial team and positions us well to accelerate our growth in 2021 and beyond," stated Rick Anderson, President and General Manager of North America. "As demonstrated by our recent announcement of customers won through benefit consultants, we believe relationships with benefits consultancies are a meaningful driver of our long-term growth. We have had early success working with benefit consultants and we believe that Claudia will help us accelerate and expand our opportunities. We are pleased that someone with Claudia's record of achievements has joined Dario to lead our broker and consultant relationships."
"I am delighted to join DarioHealth's dynamic team at a point in time when digital therapeutics and chronic condition platforms are experiencing rapid global adoption and becoming a permanent, integral part of the healthcare system," stated Ms. Kraut. "Dario employs a unique approach taking a collaborative, open-architecture model that consultants appreciate as they strive to demonstrate value to their clients. Dario's evidence-based programs, interventions and highly personalized user experience deliver superior engagement and health outcomes. Importantly, Dario's transparent sharing of data and insights related to these outcomes are highly valued and will be a competitive advantage relative to its peers."
Dario's next-generation, AI-powered, digital therapeutic approach delivers adaptive, personalized experiences designed to drive behavior change through intuitive, clinically proven digital tools and coaching that help individuals measurably improve health outcomes.
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading global digital therapeutics company revolutionizing how people with chronic conditions manage their health. By delivering evidence-based interventions driven by connected devices, data, high-quality software, and coaching, the company makes the right thing to do the easy thing to do. The company's cross-functional team operates at the intersection of life sciences, behavioral science, and software technology. Dario offers one of the highest-rated diabetes and hypertension solutions on the market its highly engaging, user-centric MyDario™ mobile app is used regularly by tens of thousands of consumers worldwide. The company is rapidly expanding into new chronic conditions and geographic markets, using a performance-based approach to improve its users' health. To learn more about DarioHealth and its digital health solutions, or for more information, visit http://dariohealth.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate," or "continue" are intended to identify forward-looking statements. For example, the Company is using forward-looking statements in this press release when it states its belief that Ms. Kraut's deep expertise and relationships in healthcare and digital therapeutics will strengthen its commercial team and positions it well to accelerate our growth in 2021 and beyond and that her hiring will help it accelerate and expand its opportunities. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
DarioHealth Corporate Contact:
Investor Relations Contact:
SOURCE DarioHealth Corp.
Company Codes: Stuttgart:LS1P, Berlin:LS1P, Munich:LS1P, NASDAQ-SMALL:DRIO